GENERIC DRUG Sample Clauses

GENERIC DRUG. The chemical equivalent of a brand-name drug with an expired patent. The color or shape may be different, but the active ingredients must be the same for both.
AutoNDA by SimpleDocs
GENERIC DRUG a drug that is available from more than one (1) manufacturing source, accepted by the Federal Food and Drug Administration (“FDA”) as a substitute for those products having the same active ingredients as a Brand Drug, and listed in the FDA “Approved Drug Products with Therapeutic Equivalence Evaluations”, otherwise known as the Orangebook, and noted as such in the pharmacy database used by the Plan.
GENERIC DRUG. A drug that has the same active ingredient as a Brand-Name Drug and is allowed to be produced after the Brand-Name Drug’s patent has expired. In determining the brand or generic classification for covered drugs, Blue Cross and Blue Shield of Montana uses the generic/brand status assigned by a nationally recognized provider of drug product database information. Not all drugs identified as a “generic” by the drug product database, manufacturer, Pharmacy or Physician may process as a Generic Drug. Generic Drugs are listed on the Drug List which is available on the Blue Cross and Blue Shield of Montana website at xxxxx://xxx.xxxxxx.xxx/rx-drugs/drug-lists/drug-lists. The Member may also contact Customer Service for more information. The geographic area of Montana in which a health carrier has a network that has been deemed adequate by the Montana Department of Health and Human Services. A list of Primary Care Providers and other Participating Providers and the communities they serve within the Geographic Service Area is available to the Member free of charge. Coverage will be provided for Habilitative Care services when the Member requires help to keep, learn or improve skills and functioning for daily living. These services include, but are not limited to:
GENERIC DRUG. A drug that has the same active ingredient as a Brand-Name Drug and is allowed to be produced after the Brand-Name Drug’s patent has expired. In determining the brand or generic classification for covered drugs, Blue Cross and Blue Shield of Montana uses the generic/brand status assigned by a nationally recognized provider of drug product database information. Not all drugs identified as a “generic” by the drug product database, manufacturer, Pharmacy or Physician may process as a Generic Drug. Generic Drugs are listed on the Drug List which is available on the Blue Cross and Blue Shield of Montana website at xxxxx://xxx.xxxxxx.xxx/rx-drugs/drug-lists/drug-lists. The Member may also contact Customer Service for more information. Coverage will be provided for Habilitative Care services when the Member requires help to keep, learn or improve skills and functioning for daily living. These services include, but are not limited to:
GENERIC DRUG increase to $10.00;
GENERIC DRUG. A prescription drug that has the same active- ingredient formula as a Brand Name Drug and has been approved by the Food and Drug Administration (FDA). The FDA rates these drugs to be as safe and effective as Brand Name Drugs.
GENERIC DRUG. A prescription drug, whether identified by its chemical, proprietary, or non-proprietary name, that is accepted by the U.S. Food and Drug Administration as therapeutically equivalent and interchangeable with drugs having an identical amount of the same active ingredient.
AutoNDA by SimpleDocs
GENERIC DRUG. A prescription drug, which is not protected by trademark registration, but is produced and sold under the chemical formulation name. 41 Home country is a country for which the insured person holds a current passport and/or to which the insured person would want to be repatriated.
GENERIC DRUG. The term

Related to GENERIC DRUG

  • FDA As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (“FDA”) under the Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (“FDCA”) that is manufactured, packaged, labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a “Pharmaceutical Product”), such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed by the Company in compliance with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration, investigational use, premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices, good clinical practices, product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure to be in compliance would not have a Material Adverse Effect. There is no pending, completed or, to the Company's knowledge, threatened, action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation) against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries has received any notice, warning letter or other communication from the FDA or any other governmental entity, which (i) contests the premarket clearance, licensure, registration, or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws or orders the withdrawal of advertising or sales promotional materials relating to, any Pharmaceutical Product, (iii) imposes a clinical hold on any clinical investigation by the Company or any of its Subsidiaries, (iv) enjoins production at any facility of the Company or any of its Subsidiaries, (v) enters or proposes to enter into a consent decree of permanent injunction with the Company or any of its Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations by the Company or any of its Subsidiaries, and which, either individually or in the aggregate, would have a Material Adverse Effect. The properties, business and operations of the Company have been and are being conducted in all material respects in accordance with all applicable laws, rules and regulations of the FDA. The Company has not been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United States of any product proposed to be developed, produced or marketed by the Company nor has the FDA expressed any concern as to approving or clearing for marketing any product being developed or proposed to be developed by the Company.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!